MTOR inhibitor-based combination therapies for pancreatic cancer


Creative Commons License

Hassan Z., Schneeweis C., Wirth M., Veltkamp C., Dantes Z., Feuerecker B., ...More

BRITISH JOURNAL OF CANCER, vol.118, no.3, pp.366-377, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 118 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.1038/bjc.2017.421
  • Journal Name: BRITISH JOURNAL OF CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.366-377
  • Keywords: MTOR, pancreatic cancer, therapeutic resistance, IN-VIVO, DUCTAL ADENOCARCINOMAS, FEEDBACK ACTIVATION, PRECLINICAL MODELS, CELL PLASTICITY, ONCOGENIC KRAS, LUNG-CANCER, TUMORIGENESIS, RESISTANCE, EGFR
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Background: Although the mechanistic target of rapamycin (MTOR) kinase, included in the mTORC1 and mTORC2 signalling hubs, has been demonstrated to be active in a significant fraction of patients with pancreatic ductal adenocarcinoma (PDAC), the value of the kinase as a therapeutic target needs further clarification.